Molecular Precision: How Myosin Inhibitors Redefine Control
Ahmad Masri, MD, MS
Anjali Owens, MD
When ß-Blockers Fall Short in oHCM: Time for a New Approach?
Modern Obstructive HCM Care: From Unmet Needs to Individualized Myosin Inhibitor Therapy
Michael Nassif, MD, MSc
From Evidence to Action: Integrating Emerging Myosin Inhibitors Into oHCM Treatment Plans
Inside the IgAN Clinic: Shared Decision-Making Into Practice
Jonathan Barratt, MD, PhD
Advancing Patient-Centered, Guideline-Driven Management of Hyperkalemia in Adults With CKD and Associated Comorbidities
June 04, 2026
Glasgow
Reframing IgAN Care: Patient-Centered Strategies to Curb Proteinuria and Preserve Kidney Function
June 05, 2026
Case-Based Approach: Managing Hyperkalemia in Patients With CKD and Heart Failure
Ellie Kelepouris, MD, FACP, FAHA
Nihar R. Desai, MD, MPH
Targeting CKD-aP at the Source: Key Mechanisms and Treatments
Steven Fishbane, MD
Maurizio Gallieni, MD
CKD-aP: Beyond the Surface
Leonie Kraft, MD
Decoding Itch in CKD: From CKD-aP Suspicion to Solution
James Burton, DM, FRCP
Lucio Manenti, MD, PhD
Emilio Sanchez, MD, PhD
CKD-aP or Something Else? Decoding the Diagnosis
Elevating CKD-aP Care: New Frontier
Improving Sleep and Mental Health in Patients with CKD-aP
Kappa-Opioid Settings: Real-World Evidence Insights
Beyond GDMT: Timely Consideration of Barostim in Heart Failure
Patrick J. McCann, MD
Rajeev Mohan, MD